Struggling MannKind sees shares rocket up on $105M-plus alliance with United on inhaled treprostinil

The long suffering MannKind Corp $MNKD is pocketing $55 million as it launches a new collaboration with United Therapeutics to use its tech to develop a dry powder formulation of the pulmonary arterial hypertension drug treprostinil.